• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000650.SZ
Share

Renhe Pharmacy Co.,Ltd Stocks

CN¥ 5.56Last Updated 15.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.08B

CN¥ 5.56
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Renhe Pharmacy Co., Ltd. is a pharmaceutical enterprise engaged in the manufacturing and distribution of a wide array of products. Its diverse portfolio includes both traditional Chinese and modern Western medicines, their essential raw materials, and various health and wellness items. These offerings are presented in numerous forms, such as oral solid preparations (e.g., tablets, capsules), liquid medications, large and small volume injectable solutions, topical treatments like lotions, liniments, and ointments, as well as suppositories and other health-related product formats. The company, which was established in 1996, maintains its corporate headquarters in Nanchang, China.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA, underpriced on P

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 19:54

Sales at Cartier's parent company were twice as strong as expected. This bolstered the luxury market

15.07.2026 19:06

Oppenheimer withdrew its recommendation to buy IBM stock following its historic plunge

15.07.2026 18:44

Kaspi.kz has completed the acquisition of Turkey's Rabobank

15.07.2026 18:25

Chip test maker Aehr extending gains after earnings and revenue beats, upbeat outlook

15.07.2026 18:04

Wholesale prices in the U.S. fell in June—a development the market did not expect

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026